Section 1 of the Mounjaro label carries two sentences that decide who this drug belongs to. A person whose A1C came back at 8.0 and whose doctor said the word tirzepatide needs the document the FDA approved, footnotes and all.<\/p>\n
The short answer, for anyone who wants it before the argument: Mounjaro for type 2 diabetes is an FDA approval covering adults and children 10 years of age and older, as an add-on to diet and exercise, plus a second approval to reduce the risk of cardiovascular death, heart attack and stroke in adults with type 2 diabetes at high cardiovascular risk. Adult dosing caps at 15 mg once weekly, pediatric dosing caps at 10 mg, and both start at 2.5 mg (Mounjaro prescribing information, DailyMed<\/a>, version 40, published 2 September 2026).<\/p>\n That label is the only place a patient can see what the trials measured.<\/p>\n Read section 1 and count the indications. The first covers glycemic control in adults and in pediatric patients 10 years of age and older with type 2 diabetes mellitus, alongside diet and exercise. The second covers reduction of major adverse cardiovascular events, defined in the label as cardiovascular death, non-fatal heart attack or non-fatal stroke, in adults with type 2 diabetes at high risk for those events.<\/p>\n The words obese and obesity appear zero times in the full text of that document, checked against the DailyMed version on 26 October 2026. This is a diabetes label.<\/p>\n Section 2.1 of the label states the schedule in its own words: “The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.” It sets the maximum at 15 mg once weekly in adults and 10 mg once weekly in pediatric patients 10 years of age and older (Mounjaro prescribing information<\/a>, section 2.1). Your prescriber owns the schedule. We describe the document, not a prescription.<\/p>\n The monotherapy trial, SURPASS-1 (NCT03954834<\/a>), ran 40 weeks and randomized 478 adults with type 2 diabetes whose blood sugar was not controlled by diet and exercise alone. Mean age was 54 years, mean duration of diabetes 4.7 years, mean BMI 32 kg\/m2, mean A1C 8.1 percent.<\/p>\n The A1C change at week 40 was minus 0.1 on placebo, minus 1.8 on 5 mg, minus 1.7 on 10 mg and minus 1.7 on 15 mg. Patients who reached an A1C under 7 percent were 23 percent on placebo against 82, 85 and 78 percent on the three doses. Fasting glucose moved minus 40 mg\/dL on the drug and plus 4 mg\/dL on placebo.<\/p>\n One detail from the trial table does more work than the headline numbers. Rescue medication, meaning an extra glucose-lowering drug added because the assigned treatment failed, went to 25 percent of the placebo group against 2 to 3 percent of the Mounjaro groups. One in four people on the sugar pill needed a second drug before the trial ended.<\/p>\n SURPASS-2 (NCT03987919<\/a>) is the comparison that sells this drug and the one most often misquoted. It randomized 1,879 adults with type 2 diabetes on stable metformin to Mounjaro 5, 10 or 15 mg once weekly, or to semaglutide 1 mg once weekly, for 40 weeks. Each arm entered at a mean A1C of 8.3 percent, mean BMI 34 kg\/m2, and a mean diabetes duration of 8.6 years. The design was open label with respect to the drug, double blind only on Mounjaro dose.<\/p>\n A1C fell 1.9 points on semaglutide 1 mg, 2.0 on Mounjaro 5 mg, 2.2 on 10 mg and 2.3 on 15 mg. The differences from semaglutide came in at 0.2 points (p<0.05), 0.4 points (p<0.001) and 0.5 points (p<0.001). An A1C under 7 percent arrived for 79 percent on semaglutide and 82, 86 and 86 percent on the three Mounjaro doses, with the statistical significance marked on the 10 and 15 mg columns only.<\/p>\n Juan Pablo Fr\u00edas, M.D., of the National Research Institute, an investigator on the SURPASS program, put the program’s claim this way in the company’s approval announcement: “Mounjaro delivered superior and consistent A1C reductions against all of the comparators throughout the SURPASS program” (Eli Lilly, FDA approves Lilly’s Mounjaro injection<\/a>, 13 May 2022).<\/p>\n Superior is accurate and the arithmetic stays modest. A two-tenths-of-a-point edge at 5 mg is small, and tolerance decides which dose a person reaches. In the pooled placebo-controlled adult trials, gastrointestinal reactions hit 20.4 percent on placebo and 37.1, 39.6 and 43.6 percent at 5, 10 and 15 mg, while discontinuation for those reactions ran 0.4 percent on placebo against 3.0, 5.4 and 6.6 percent. The best A1C number belongs to the dose about one in fifteen people stopped taking.<\/p>\n The cardiovascular indication rests on SURPASS-CVOT (NCT04255433<\/a>), and this is the part of the label that deserves a slow read. The trial randomized 13,299 adults with type 2 diabetes and established cardiovascular disease to Mounjaro up to 15 mg once weekly or to dulaglutide 1.5 mg once weekly, an active comparator rather than a placebo. Mean age was 64 and 47 percent had a prior heart attack. Median follow-up ran 210.1 weeks, a little over four years.<\/p>\n The primary endpoint, first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke, came in at 803 events (12.1 percent) on Mounjaro against 863 (13.0 percent) on dulaglutide, hazard ratio 0.92 with a 95.3 percent confidence interval of 0.83 to 1.01. The label states the result plainly: Mounjaro was non-inferior to dulaglutide, and superiority to dulaglutide was not established. Non-inferior here means the drug did not lose. It does not mean the drug won, and the confidence interval crosses 1.00, so the honest reading is a possible small benefit sitting on top of a possible small harm.<\/p>\n All-cause death is the row that travels on social media: 567 deaths (8.5 percent) on Mounjaro against 670 (10.1 percent) on dulaglutide, hazard ratio 0.84 with an interval of 0.75 to 0.94. The label’s own table footnote marks that row, along with every component endpoint, as not controlled for family-wise type I error rate. Translation for a patient: that comparison was not built to survive the statistical correction a claim of proven mortality benefit requires, and the FDA did not grant the claim.<\/p>\n The pediatric indication rests on SURPASS-PEDS (NCT05260021<\/a>), a 30-week double-blind trial with a 22-week open-label extension that randomized 99 patients aged 10 and older. Mean age was 15 years, mean A1C 8.0 percent, mean weight 97 kg, mean BMI 35 kg\/m2, and mean diabetes duration 2.4 years. At entry, 69 percent took metformin, 8 percent basal insulin, and 23 percent both.<\/p>\n A1C fell 0.2 points on placebo, 1.9 on 5 mg and 2.2 on 10 mg, with the pooled drug arms at 2.0. An A1C at or under 6.5 percent arrived for 28 percent on placebo against 68, 81 and 75 percent. BMI moved minus 0.5 percent on placebo against minus 6.9, minus 10.8 and minus 8.8 percent, which is a measurable change in a 15-year-old.<\/p>\n The cost shows up in the hypoglycemia table. Among children on basal insulin, blood glucose under 54 mg\/dL occurred in 10 percent on placebo, 30 percent on 5 mg and 27 percent on 10 mg. Among children on metformin alone, the rates were 4, 9 and 9 percent. No severe hypoglycemia appeared in the trial, and the label notes that vomiting, abdominal pain and hypoglycemia ran higher in children than in adults. The same label sets the pediatric ceiling at 10 mg, so a teenager whose sugar stays high cannot climb to the 12.5 and 15 mg strengths an adult can reach. The FDA’s approval record for this drug lists an efficacy supplement approved 19 December 2025 (Drugs@FDA, NDA 215866<\/a>), and the label now carries the age 10 line.<\/p>\n Clinics sell tirzepatide, and the word on the vial does not guarantee the molecule in the trial tables above. The FDA’s position page states that compounded drugs are not FDA approved, and that the agency does not review them for safety, effectiveness or quality (FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss<\/a>, accessed 26 October 2026). The agency also flags telehealth sellers that claim a compounded version matches an approved drug.<\/p>\n For a person with type 2 diabetes the question is sharper than for a person buying for weight, because those numbers belong to a specific product with an approval, a boxed warning, a National Drug Code and a 40-page label. A vial with no NDC cannot be checked against any trial data in this article. Our checklist for reading a clinic before booking sits in how to check a peptide clinic before booking<\/a>, our clinic directory<\/a> lists practices by city, and the label’s own side effect tables are laid out in tirzepatide side effects on the label<\/a>.<\/p>\n One distinction catches people: Mounjaro and Zepbound hold the same molecule under separate approvals, and the weight indication belongs to Zepbound. We walked through that split in Mounjaro for weight loss<\/a>, and the starting schedule is in Mounjaro dosage<\/a>. The weight result under its own approval is in Zepbound for weight loss: the 20.9% is a group average<\/a>.<\/p>\n Yes. The current label covers pediatric patients 10 years of age and older with type 2 diabetes, as an add-on to diet and exercise, and the pediatric maximum dose is 10 mg once weekly against 15 mg for adults. Safety and effectiveness below age 10 have not been established.<\/p>\n In SURPASS-1, a 40-week trial in 478 adults, A1C fell 1.8 points at 5 mg, 1.7 at 10 mg and 1.7 at 15 mg, against 0.1 on placebo. The average starting A1C was 8.1 percent, and a group average is not a promise for one person.<\/p>\n In SURPASS-2, the 10 and 15 mg doses beat semaglutide 1 mg by 0.4 and 0.5 A1C points at 40 weeks, and 5 mg beat it by 0.2. All three differences were statistically significant, the first two at p<0.001 and the third at p<0.05.<\/p>\n The label carries an approval to reduce the risk of cardiovascular death, non-fatal heart attack and non-fatal stroke in adults with type 2 diabetes at high cardiovascular risk. The supporting trial compared Mounjaro with dulaglutide, found it non-inferior, and did not establish superiority, with a hazard ratio of 0.92 and an interval of 0.83 to 1.01.<\/p>\n The label caps pediatric patients 10 years and older at 10 mg once weekly, reached through 2.5 mg steps after at least four weeks on the prior dose. Which dose a young patient reaches is a decision for the prescriber who can see the A1C trend and the side effects.<\/p>\n Compounded tirzepatide is not the FDA-approved product, and the agency states that compounded drugs do not go through its review for safety, effectiveness or quality. A compounded vial has no approval, and its contents cannot be matched to the trial numbers in this article. Patients who want the drug in the trials need the approved product and a prescription.<\/p>\n This article is general information for people researching peptide and GLP-1 treatment, and it is not medical advice. Doses vary by person and by prescriber, so we describe what the label and the trials say rather than what any individual should take. Compounded products are not FDA-approved, and no compounded vial can be presented as the drug in these trials.<\/p>\nMounjaro for Type 2 Diabetes – Two Indications and No Scale Anywhere<\/h2>\n
SURPASS-1 – 478 Patients and a Placebo Group That Needed Rescuing<\/h2>\n
SURPASS-2 – 15 mg Beats Semaglutide, 5 mg Wins by Two Tenths<\/h2>\n
Mounjaro for Type 2 Diabetes and the Heart – 803 Events Against 863<\/h2>\n
SURPASS-PEDS – 99 Children and a 10 mg Ceiling<\/h2>\n
Compounded Tirzepatide – Same Word, No Approval<\/h2>\n
Frequently asked questions<\/h2>\n
Is Mounjaro approved for type 2 diabetes in children?<\/h3>\n
How much does Mounjaro lower A1C?<\/h3>\n
Is Mounjaro stronger than semaglutide for type 2 diabetes?<\/h3>\n
Does Mounjaro prevent heart attacks?<\/h3>\n
What is the highest dose of Mounjaro for a child?<\/h3>\n
Can I get Mounjaro as a compounded peptide?<\/h3>\n
Sources<\/h2>\n
\n